Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Stock price

<< Previous

Bullboard Posts

Next >>

Comment by Marky1on Mar 06, 2021 5:59pm

160 Views

Post# 32737211

RE:RE:Stock price

Thank you Calgary for your work....According to what you said. 661,828 or 53% of the shares have been transferred to the shareholders of AH...That leaves only another 578,172 or 47% of the shares left to be transferred
Hopefully the transfer will be over by the end of next week...
We could finallll th orle that we are a much stronger company now, owning all the patents of H2S technology and we have enough money to go it alone
Much simpler to deal with 1 strong company than 2 entities
Come on Dr. Haut'....Deal Time with Bayer is within your abilities
1B$ USD is the bare minimum that ATE is worth...probably a lot more
GLTA

<< Previous

Bullboard Posts

Next >>

Fortune Minerals receives funding for NICO project development